Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02041260

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Differentiated Thyroid Cancer (DTC) Clinical Trial

Official title:
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Clinical Trial Summary

Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD. Subjects can receive drug as long as they continue to derive clinical benefit or until they experience unacceptable drug-related toxicity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02041260
Study type Interventional
Source Thomas Jefferson University
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 2014
Completion date May 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT01788982 - Nintedanib(BIBF1120) in Thyroid Cancer Phase 2
Completed NCT02966093 - A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Phase 3
Completed NCT02432274 - Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Phase 1/Phase 2